Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cixutumumab + Everolimus + Octreotide acetate |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cixutumumab | IMC-A12 | IGF1R Antibody 8 | Cixutumumab (IMC-A12) is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (PMID: 29520435, PMID: 29909907). | |
Everolimus | Afinitor | RAD001|Zortress | mTORC1 Inhibitor 9 | Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, in adult and pediatric patients aged 1 year and older with tuberous sclerosis complex who have subependymal giant cell astrocytoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov). |
Octreotide acetate | Sandostatin Lar Depot | SMS 201-995 | Sandostatin Lar Depot (octreotide acetate) mimics the activity of somatostatin, which may control the growth of neuroendocrine tumors (PMID: 26605828). Sandostatin Lar Depot (octreotide acetate) is FDA approved for symptom control in patients with carcinoid tumors and VIPomas (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|